Korea Bio-Gen Co.Ltd
KBG Corp. produces and supplies a range of fine chemicals in South Korea and internationally. The company offers silicone chemicals, such as functional organosilanes, functional silicone polymers, silicone resins and intermediates, silicone pressure sensitive adhesives, and silicone materials for electronics; specialty chemicals, including polymerization inhibitors; and food additives, as well as… Read more
Korea Bio-Gen Co.Ltd (318000) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.040x
Based on the latest financial reports, Korea Bio-Gen Co.Ltd (318000) has a cash flow conversion efficiency ratio of 0.040x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.85 Billion) by net assets (₩46.23 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Korea Bio-Gen Co.Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Korea Bio-Gen Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Korea Bio-Gen Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Korea Bio-Gen Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Donkeyrepublic Holding AS
CO:DONKEY
|
0.025x |
|
P&K Skin Research Center Co. Ltd
KQ:347740
|
0.021x |
|
Far East Gold Ltd
AU:FEG
|
-0.003x |
|
KRY
F:KRY
|
0.032x |
|
Asia Economy Daily Co Ltd
KQ:127710
|
0.254x |
|
Haiwan International Development Co Ltd
TWO:3252
|
0.019x |
|
Yigit Aku Malzemeleri Nakliyat Turizm Insaat Sanayi ve Ticaret A.S.
IS:YIGIT
|
N/A |
|
Spirit Technology Solutions Ltd
AU:ST1
|
-0.027x |
Annual Cash Flow Conversion Efficiency for Korea Bio-Gen Co.Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Korea Bio-Gen Co.Ltd from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩44.91 Billion | ₩4.29 Billion | 0.096x | -57.57% |
| 2023-12-31 | ₩42.05 Billion | ₩9.47 Billion | 0.225x | +371.25% |
| 2022-12-31 | ₩34.95 Billion | ₩1.67 Billion | 0.048x | -51.19% |
| 2021-12-31 | ₩31.61 Billion | ₩3.09 Billion | 0.098x | +6.83% |
| 2020-12-31 | ₩28.16 Billion | ₩2.58 Billion | 0.092x | -22.91% |
| 2019-12-31 | ₩25.69 Billion | ₩3.05 Billion | 0.119x | -34.28% |
| 2018-12-31 | ₩10.97 Billion | ₩1.98 Billion | 0.181x | +16.60% |
| 2017-12-31 | ₩8.93 Billion | ₩1.38 Billion | 0.155x | -- |